Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
Conditions
- Advanced Cervical Adenocarcinoma
- Advanced Vaginal Carcinoma
- Advanced Vulvar Carcinoma
- Human Papillomavirus-Related Cervical Squamous Cell Carcinoma
- Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma
- Metastatic Cervical Adenocarcinoma
- Metastatic Cervical Carcinoma
- Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Metastatic Vaginal Adenocarcinoma
- Metastatic Vaginal Carcinoma
- Metastatic Vulvar Carcinoma
- Recurrent Cervical Adenocarcinoma
- Recurrent Cervical Carcinoma
- Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Recurrent Vaginal Carcinoma
- Recurrent Vulvar Carcinoma
- Stage III Cervical Cancer AJCC v8
- Stage III Vaginal Cancer AJCC v8
- Stage III Vulvar Cancer AJCC v8
- Stage IIIA Cervical Cancer AJCC v8
- Stage IIIA Vulvar Cancer AJCC v8
- Stage IIIB Cervical Cancer AJCC v8
- Stage IIIB Vulvar Cancer AJCC v8
- Stage IIIC Vulvar Cancer AJCC v8
- Stage IV Cervical Cancer AJCC v8
- Stage IV Vaginal Cancer AJCC v8
- Stage IV Vulvar Cancer AJCC v8
- Stage IVA Cervical Cancer AJCC v8
- Stage IVA Vaginal Cancer AJCC v8
- Stage IVA Vulvar Cancer AJCC v8
- Stage IVB Cervical Cancer AJCC v8
- Stage IVB Vaginal Cancer AJCC v8
- Stage IVB Vulvar Cancer AJCC v8
- Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
- Vulvar Adenocarcinoma
- Vulvar Squamous Cell Carcinoma
Interventions
- BIOLOGICAL: Durvalumab
- OTHER: Laboratory Biomarker Analysis
- RADIATION: Stereotactic Radiosurgery
- BIOLOGICAL: Tremelimumab
Sponsor
M.D. Anderson Cancer Center
Collaborators